By Susan Kelly (Reuters) - Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential. Amgen shares rose 9 percent in midday trade on news of the acquisition, the biggest biotech deal since Gilead Sciences Inc's $11 billion purchase of Pharmasset in 2012. The main prize in the acquisition is Onyx's blood cancer drug Kyprolis. ...
via Health News Headlines - Yahoo! News http://news.yahoo.com/amgen-seeks-bolster-drug-pipeline-10-4-billion-002654698.html
via Health News Headlines - Yahoo! News http://news.yahoo.com/amgen-seeks-bolster-drug-pipeline-10-4-billion-002654698.html
No comments:
Post a Comment